Disc Medicine Announces Collaboration with National Institutes of Health for Phase II Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a Phase II clinical study of patients with DBA.